In the second part of the Heard at HLTH series, executives from BrightInsight, Iodine Software, Intelligent Medical Objects, Carrum Health, Clarify Health and Trayt Health shared new developments across their businesses and perspectives on value-based care at the HLTH 2023 event.
At the 5th annual HLTH conference in Las Vegas, 14 healthcare executives from companies such as Babson Diagnostics to Wheel responded to questions such as what's the difference between a positive and negative user experience in telehealth? They also previewed their plans for 2023.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
BrightInsight developed the Disease Management Solution to help biopharma and medtech companies bring their Software as a Medical Device (SaMD) to market faster, according to BrightInsight CEO and Co-founder Dr. Kal Patel.
In order to benefit from the Virtual1Care trend, pharma and medtech companies must ensure that their digital health tools, wrapped around a drug or device, comply with evolving regulations.
Digital health thought leader Mark Tarby, BrightInsight vice president of regulatory and quality management systems, shared his take on what the EU MDR means for connected devices, Software as a Medical Device (SaMD), and the go-to market strategies for the companies behind them.
BrightInsight, a startup developing infrastructure to make it easier for companies to make their own health apps, raised $101 million in funding. General Catalyst led the series C round.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
AstraZeneca is turning to digital technology to help patients and clinicians manage the treatment of chronic diseases. Though this technology isn’t tied to any AstraZeneca drug, the company believes such digital tools will become part of the new standard of care.
In an interview, BrightInsight Co-founder and CEO Kal Patel, MD, offered a preview of the report, The Role of Digital Health in Immuno-oncology Therapy Development and Adoption.
The disruption to biopharma and medtech businesses caused by Covid-19, such as product launch and clinical trial delays, has underscored the need for a more digital focused strategy.
MedCity spoke with Evidation and BrightInsight, two startups that have recently announced funding rounds, amid a Covid-19 pandemic worsening in the U.S.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
BrightInsight, a startup developing an IoT platform for medical device and biopharma companies, closed a $40 million series B funding round. The company recently struck two partnerships with AstraZeneca and CSL Behring.
Kal Patel, MD, CEO and co-founder of BrightInsight, highlighted the value of using a regulated Internet of Things (IoT) infrastructure to host and manage digital health products in an interview with MedCity News.
San Jose-based BrightInsight is a spin-off from contract manufacturer Flex and has raised funding for its internet-of-things platform for connected medical devices and drug delivery systems.